With accelerating development of treatments for ataxias, biomarkers are needed as end-points in clinical trials. The Ataxia Global Initiative MRI Biomarkers Working Group has published recommendations for the use of MRI measures as end-points in clinical trials in the most common forms of ataxia. Access to this article via Institution of Civil Engineers Library is not available. Teive, H. A. G. & Ashizawa, T. Primary and secondary ataxias. Curr. Opin. Neurol. 28 , 413–422 (2015). Öz, G. et al. MRI end-points for clinical trials in ataxias: recommendations from the Ataxia Global Initiative MRI Biomarkers Working Group. Nat. Rev. Neurol. https://doi.org/10.1038/s41582-026-01218-7 (2026). Ashizawa, T., Öz, G. & Paulson, H. L. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat. Rev. Neurol. 14 , 590–605 (2018). Eisel, M. L. S. et al. Emerging therapies in hereditary ataxias. Trends Mol. Med. 31 , 181–194 (2025). Lynch, D. R. et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann. Neurol. 89 , 212–225 (2021). Schmitz-Hübsch, T. et al.
With accelerating development of treatments for ataxias, biomarkers are needed as end-points in clinical trials. The Ataxia Global Initiative MRI Biomarkers Working Group has published recommendations for the use of MRI measures as end-points in clinical trials in the most common forms of ataxia.
Access to this article via Institution of Civil Engineers Library is not available.
Teive, H. A. G. & Ashizawa, T. Primary and secondary ataxias. Curr. Opin. Neurol. 28 , 413–422 (2015).
Öz, G. et al. MRI end-points for clinical trials in ataxias: recommendations from the Ataxia Global Initiative MRI Biomarkers Working Group. Nat. Rev. Neurol. https://doi.org/10.1038/s41582-026-01218-7 (2026).
Ashizawa, T., Öz, G. & Paulson, H. L. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat. Rev. Neurol. 14 , 590–605 (2018).
Eisel, M. L. S. et al. Emerging therapies in hereditary ataxias. Trends Mol. Med. 31 , 181–194 (2025).
Lynch, D. R. et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann. Neurol. 89 , 212–225 (2021).
Schmitz-Hübsch, T. et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66 , 1717–1720 (2006).
Subramony, S. H. et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64 , 1261–1262 (2005).
Klockgether, T. et al. Paving the way toward meaningful trials in ataxias: an Ataxia Global Initiative perspective. Mov. Disord. 37 , 1125–1130 (2022).
Öz, G. et al. MR imaging in ataxias: consensus recommendations by the Ataxia Global Initiative Working Group on MRI Biomarkers. Cerebellum 23 , 931–945 (2024).
Klockgether, T., Synofzik, M. & AGI working group on COAs and Registries. Consensus recommendations for clinical outcome assessments and registry development in ataxias: Ataxia Global Initiative (AGI) working group expert guidance. Cerebellum 21 , 924–930 (2024).
Movement Disorders Unit, Neurology Service, Internal Medicine Department, Hospital de Clínicas, The Federal University of Paraná, Curitiba, Brazil
Teive, H.A.G. Ataxia Global Initiative recommend MRI end-points for clinical trials in ataxias. Nat Rev Neurol (2026). https://doi.org/10.1038/s41582-026-01242-7